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Background
The efficacy of tamoxifen as a breast cancer (BC) pre-
vention strategy for BRCA1 and BRCA2 mutation car-
riers is uncertain.
Patients and methods
Female BRCA1 and BRCA2 mutation carriers, with a per-
sonal history of BC since 1970, enrolled in any of the BC
family studies, kConFab (Kathleen Cuningham Founda-
tion Consortium for Research into Familial Breast Can-
cer), IBCCS (International BRCA1 and BRCA2 Carrier
Cohort Study), or BCFR (Breast Cancer Family Registry)
were eligible. Those with bilateral disease at first BC diag-
nosis, tamoxifen use prior to their first BC diagnosis, or
another invasive cancer with were excluded. Data were
self-reported at entry into the cohort and at follow-up.
Hazard ratios (HRs) for development of contralateral BC
associated with tamoxifen use after first BC diagnosis
were estimated using Cox proportional hazards, model-
ing time from diagnosis of first primary BC, adjusting for
year of birth (continuous), age at diagnosis (continuous),
country and bilateral oophorectomy (yes/no, time-vary-
ing). Data were censored at contralateral mastectomy,
death or loss to follow-up.
Results
Of 1642 BRCA1 and 919 BRCA2 mutation carriers, 374
(23%) and 444 (48%), respectively, took tamoxifen after
their first BC diagnosis. During 21,344 person-years of
follow-up, 596 contralateral BCs were observed. Overall,
the adjusted HR estimates were 0.31 (95% CI: 0.22-0.45)
and 0.24 (95% CI 0.16-0.35) for BRCA1 and BRCA2
mutation carriers, respectively. After left-truncating the
analysis at time of recruitment, the adjusted HR esti-
mates were 0.52 (95% CI: 0.26-1.04) and 0.39 (95% CI:
0.17-0.89) from studying 629 BRCA1 and 412 BRCA2
mutation carriers, respectively, with 4,869 person-years
of follow-up.
Conclusions
Although biased estimates due to non-random use of
tamoxifen cannot be excluded, these results are consis-
tent with tamoxifen reducing BC risk for both BRCA1
and BRCA2 mutation carriers.
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